Duaa Kanan, MD

Excited to share our new publication with @NarjustFlorezMD @MImbimbo1 @COlazagasti on lung cancer diagnosed during pregnancy — a rare and highly complex clinical scenario requiring multidisciplinary care. frontiersin.org/journals/oncol…

@Florez_Lab @AbioyeOyepejuMD @Fakoo_Olayinka @NarjustFlorezMD @crisbergerot @KellyMezaMD @royaryam Happy birthday Ola 🥳🥳

Happy Birthday @Fakoo_Olayinka one of our amazing research assistants! 🎉 We truly appreciate all that you do at the Florez Lab. Your hard work, dedication, and support do not go unnoticed. Wishing you a year filled with joy, success, and abundant blessings. 🙏🏽✨

🚨 M-EPIC RESEARCH STUDY IS LIVE 🚨 Assessing oncology education in the U.S. IM residency programs, led by @duaakanan21 🎁 Chance to win 1 of 10 $50 gift cards 📩 DM @florez_lab or @duaakanan21 📧 dkanan@uvm.edu

Please help us make an impact on the future of oncology education! 📢 The M-EPIC initiative is the first national assessment of oncology education among internal medicine resident physicians in the USA that aims to identify gaps and key areas for improvement

🚨 M-EPIC RESEARCH STUDY IS LIVE! Assessing oncology education in the U.S. IM residency programs, led by @duaakanan21 🩺 🎁 Chance to win 1 of 10 $50 gift cards. 📝 DM @Florez_Lab or @duaakanan21 📧 dkanan@uvm.edu @IMG_Oncologists @oncodaily @hemeoncfellow @dominicandoc2

🚨 M-EPIC RESEARCH STUDY IS LIVE! We’re assessing oncology education in U.S. IM residency programs—led by @duaakanan21 🎁 Complete the survey for a chance to win 1 of 10 $50 gift cards. 📝 To take the survey, DM @florez_lab @duaakanan21 📧 Or email: dkanan@uvm.edu

@TumorBoardTues @NarjustFlorezMD @Latinamd @benlevylungdoc @LealTiciana @MMarmarelis @lungoncdoc @KelseyPanMD @BRicciutiMD @BrunaPellini @ADesaiMD @MPishvaian @dominicandoc2 @DrRoyHerbst @royaryam @IvyLorena_Md @EgfrUk @DFEGFRcenter @EGFRResisters Thank you so much for joining us! 🙏 #ASCO26 should be exciting, keep an eye on updates in perioperative IO, EGFR-targeted strategies (including NeoADAURA), and ctDNA/MRD-guided approaches in early-stage #NSCLC 👀 And yes—don’t forget to test what you learned! 😊

@NarjustFlorezMD @NEJM @DanaFarber Huge congratulations Dr. @NarjustFlorezMD 👏👏👏

Grateful to take on a new role as Associate Editor of New England Journal Medicine Clinician. Advancing how we communicate science is key to delivering better, more informed care for our patients. @NEJM @DanaFarber clinician.nejm.org/editors/AU3755

📢 Calling all oncology physicians Take part in “The Hidden Struggle” — a global survey exploring anxiety, depression, and access to mental health resources in oncology. ⏱️ ~10 min | 🔒 Anonymous 👉 surveymonkey.com/r/TZXMQXG Led by Dr. @COlazagasti

@NarjustFlorezMD @TumorBoardTues @Latinamd @benlevylungdoc @StephenVLiu @LealTiciana @MMarmarelis @lungoncdoc @KelseyPanMD @BRicciutiMD @BrunaPellini @ADesaiMD @MPishvaian @dominicandoc2 14/23 #TumorBoardTuesday 📌 HR 0.23 (95% CI: 0.15-0.36) 👉 MRD assess risk—but should NOT be used to omit adjuvant osimertinib in eligible EGFR+ #NSCLC. nature.com/articles/s4159…

@NehemiasGuevar5 @TumorBoardTues @Latinamd @benlevylungdoc @StephenVLiu @LealTiciana @MMarmarelis @lungoncdoc @KelseyPanMD @BRicciutiMD @BrunaPellini @ADesaiMD @MPishvaian @dominicandoc2 @DrRoyHerbst @royaryam @IvyLorena_Md @EgfrUk @DFEGFRcenter @EGFRResisters #TumorBoardTuesday On the primary endpoint of major pathologic response (MPR) analyzed by blinded central pathology review, MPR rates were 26% with osi+chemo and 25% with osi, respectively, compared with 2% in the placebo+chemo group. ascopubs.org/doi/10.1200/JC… 20/23

#TumorBoardTuesday In the NeoADAURA phase 3 trial, patients with resectable EGFR-mutated stage II-IIIB NSCLC were randomized to osi 80 mg daily for 9+ weeks plus pt-based chemo vs chemo alone Pt-based chemo was given Q3W x 3 cycles. Following surgery, adjuvant osi was offered Design

Patient empowerment is care. When patients feel informed and supported, they reclaim their voice and choices. Knowledge is power. Compassion makes the difference. youtu.be/ZHWrTQjabu4?si…

🧠✨ Happening TODAY! Join us at 8 PM ET for a deep dive into early-stage #NSCLC & #NeoADAURA Excited to join @NarjustFlorezMD — don’t miss it! #TumorBoardTuesday #LungCancer @oncodaily @Florez_Lab @mgonzalezvelMD @MomaVelez11 @dominicandoc2 @Arthur_Aung @JorgeOct_

Genetic testing in cancer care is underused, especially in underserved populations This paper @JCOOA_ASCO offers a practical, tumor-based roadmap to identify patients who should be referred for germline evaluation ascopubs.org/doi/pdfdirect/…

With #ASCO26 just around the corner, and even though will sadly miss it this year, please find my tips and tricks about how to approach your favorite KOL. connection.asco.org/do/approaching…

Register today for our Annual Symposium!

Before you call it MDS, check a copper level — vacuolized precursors on the marrow are your clue, and the cytopenias are completely reversible. Who gets copper deficiency? Bariatric surgery patients People who take too much zinc supplements

Excited to share this work, led by Dr. @COlazagasti Looking forward to her presentation at the ASCO Annual Meeting—honored to be part of such an amazing team. Survey still open, oncology colleagues, we welcome your perspective. @NarjustFlorezMD @MomaVelez11 @Florez_Lab

🚨 #ASCO26 abstract titles are finally out! This year's Plenary Session will feature 2⃣ phase 3 trials for our 🫁 Thoracic Oncology community: 🔷 Primary results of LIBRETTO-432: adjuvant selpercatinib in RET+ NSCLC. Presented by Dr. Jonathan Goldman @UCLA with discussion by @christine_lovly @cityofhope 🔷 Overall survival of HARMONi-6: Ivonescimab + chemo vs. Tislelizumab + chemo in squamous NSCLC. Presented by Prof. Shun Lu from Shanghai Chest Hospital with discussion by Dr. Julie Brahmer @JohnsHopkins #LungCancer #LCSM @ASCO @IASLC